Treatment of viral hepatitis in China: Better clinical research and improved practice

Chinese Medical Journal

Volumn 122, Issue 19, 2009, Pages 2236-2238

  Chen, Jing ^a   Jia, Ji Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Advance; China; Therapeutics; Viral hepatitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE;

CHINA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HEPATITIS B; HEPATITIS C; HUMAN; MEDICAL LITERATURE; PUBLICATION; REVIEW; VIRUS HEPATITIS;

CHINA; HEPATITIS B; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70350604359     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.19.008     Document Type: Review

References (21)

1. Jia JD. Hepatitis B in China: from Guideline to Practice. Virologica Sinica 2008; 23: 152-155.
2. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-391.
3. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29 Suppl 1: s1-s8.
4. Wu TX, Li YP, Li J, Liu GJ. A milestone for clinical trials: establishment of a global clinical trial registration system. Chinese Clinical Trial Register, MOH Chinese Evidence-Based Medicine Centre, Chinese Cochrane Centre, INCLEN CERTC in West China Hospital, Sichuan University. (Accessed on October 2000 at http://www.chictr.org/Upload/milestone.pdf )
5. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
6. Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J 1999; 112: 387-391. (Pubitemid 29234839)
7. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108-116. (Pubitemid 44049144)
8. Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int 2008; 2: 486-493.
9. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454. (Pubitemid 351280712)
10. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 2006; 58: 1031-1035.
11. Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44: 541-548. (Pubitemid 46233256)
12. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
13. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
14. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
15. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
16. Chinese Society of Infectious Diseases, Chinese Society of Hepatotogy. A protocol for the prevention and treatment of viral hepatitis. Chin Med J 2001; 40: 62-68.
17. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Guideline of prevention and treatment of hepatitis C. Chin J Hepatol (Chin) 2004; 12: 194-198.
18. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Guideline on the prevention and treatment of chronic hepatitis B. Chin J Hepatol (Chin) 2005; 13: 881-891.
19. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J 2007; 120: 2159-2173.
20. Jia JD, Zhuang H. A winning war against hepatitis B virus infection in China. Chin Med J 2007; 120: 2157-2158.
21. The Bristol-Myers Squibb Foundation Combats Chronic Hepatitis B in Asia. (Accessed on November 13, 2007 at http://www.businesswire.com/news/bms/ 20090202005953/en).